194487-79-1

Usage

Uses

Used in Pharmaceutical Synthesis:
(S)-2-(1-Amino-ethyl)-4-bromo-benzoic acid methyl ester is used as an intermediate in the pharmaceutical industry for the synthesis of various drugs and organic compounds. Its unique structure and reactivity make it a valuable building block in the development of new medications.
Used in Chemical Research:
In the field of chemical research, (S)-2-(1-Amino-ethyl)-4-bromo-benzoic acid methyl ester is utilized as a subject for studying its properties, reactivity, and potential applications in organic synthesis. This research can lead to the discovery of new compounds and materials with beneficial properties.

Upstream product

• 67-56-1 methanol 
• 644984-78-1 4-bromo-2-ethylbenzoic acid 
• 2386-64-3 ethylmagnesium chloride 
• 112704-79-7 2-fluoro-4-bromobenzoic acid 
• 74-88-4 methyl iodide 
• 68837-59-2 4-bromo-2-methylbenzoic acid 

Downstream Products

• 935260-96-1 methyl 4-cyano-2-ethylbenzoate 
• 1227090-87-0 methyl 2-(4-bromo-2-ethylphenyl)acetate 
• 855931-72-5 2-(4-bromo-2-ethylphenyl)acetic acid 
• 877131-20-9 2-(4-bromo-2-ethylphenyl)acetonitrile 
• 877131-21-0 (4-bromo-2-ethylphenyl)methanol 
• 552330-86-6 5-bromoisoindolin-1-one 

Relevant academic research and scientific papers

MACROCYCLIC COMPOUND AND USE THEREOF

A compound represented by the following formula (I): wherein each symbol in the formula is as described herein or a salt thereof has an NRF2 activating activity, and is expected to be useful as a preventive or therapeutic agent for diseases associated with oxidative stress, in particular, hepatic disease (for example, non-alcoholic steatohepatitis (NASH)), cardiovascular disease (for example, heart failure or pulmonary arterial hypertension), lung disease (for example, chronic obstructive pulmonary disease (COPD)), kidney disease (for example, chronic kidney disease (CKD) or acute kidney injury (AKI)), central nervous system disease (for example, Parkinson's disease), mitochondrial disease (for example, Friedreich motor ataxia, mitochondrial myopathy), inflammatory disease (for example, multiple sclerosis (MS), inflammatory bowel disease (IBD)), sickle cell disease, cancer, or the like.

BENZOFURANE AND BENZOTHIOPHENE DERIVATIVES AS PGE2 RECEPTOR MODULATORS

The present invention relates to benzofurane and benzothiophene derivatives of formula (I) Formula (I) wherein (R1)n, R2, R3, R4a, R4b, R5a, R5b and Ar1 are as described in the description and their use in the treatment of cancer by modulating an immune response comprising a reactivation of the immune system in the tumor. The invention further relates to novel benzofurane and benzothiophene derivatives of formula (II) and their use as pharmaceuticals, to their preparation, to pharmaceutically acceptable salts thereof, and to their use as pharmaceuticals, to pharmaceutical compositions containing one or more compounds of formula (I), and especially to their use as modulators of the prostaglandin 2 receptors EP2 and/or EP4.

PYRIMIDINE DERIVATIVES AS PGE2 RECEPTOR MODULATORS

The present invention relates to pyrimidine derivatives of formula (I) wherein (R1)n, R3, R4a, R4b, R5a, R5b and Ar1 are as described in the description and their use in the treatment of cancer by modulating an immune response comprising a reactivation of the immune system in the tumor. The invention further relates to novel benzofurane and benzothiophene derivatives of formula (II) and their use as pharmaceuticals, to their preparation, to pharmaceutically acceptable salts thereof, and to their use as pharmaceuticals, to pharmaceutical compositions containing one or more compounds of formula (I), and especially to their use as modulators of the prostaglandin 2 receptors EP2 and/or EP4.

PHENYL DERIVATIVES AS PGE2 RECEPTOR MODULATORS

The present invention relates to phenyl derivatives of formula (I) Formula (I) wherein (R1)n, R3, R4a, R4b, R5b and Ar1 are as described in the description and their use in the treatment of cancer by modulating an immune response comprising a reactivation of the immune system in the tumor. The invention further relates to novel benzofurane and benzothiophene derivatives of formula (III) and their use as pharmaceuticals, to their preparation, to pharmaceutically acceptable salts thereof, and to their use as pharmaceuticals, to pharmaceutical compositions containing one or more compounds of formula (I), and especially to their use as modulators of the prostaglandin 2 receptors EP2 and/or EP4.

HISTONE DEMETHYLASE INHIBITORS

Provided herein are substituted pyrazolylpyridine, pyrazolylpyridazine, and pyrazolylpyrimidine derivative compounds and pharmaceutical compositions comprising said compounds. The subject compounds and compositions are useful for inhibition histone demethylase. Furthermore, the subject compounds and compositions are useful for the treatment of cancer, such as prostate cancer, breast cancer, bladder cancer, lung cancer and/or melanoma and the like.

INHIBITORS OF HEPATITIS C VIRUS RNA-DEPENDENT RNA POLYMERASE, AND COMPOSITIONS AND TREATMENTS USING THE SAME

The present invention provides compounds of formula (4), and their pharmaceutically acceptable salts and solvates, which are useful as inhibitors of the Hepatitis C virus (HCV) polymerase enzyme and are also useful for the treatment of HCV infections in HCV-infected mammals. The present invention also provides pharmaceutical compositions comprising compounds of formula (4), their pharmaceutically acceptable salts and solvates. Furthermore, the present invention provides intermediate compounds and methods useful in the preparation of compounds of formula (4).